Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the <i>Fmr1</i>-KO Mouse Model of Fragile X Syndrome
Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remain...
| الحاوية / القاعدة: | Cells |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
MDPI AG
2023-07-01
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.mdpi.com/2073-4409/12/15/1927 |
